New strategy enhances immunotherapy effectiveness against glioblastoma by utilizing gut microbes

Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma

Glioblastoma (GBM), the most common adult primary brain tumor, has an average survival of only 15–18 months. Recently, the combination of immune checkpoint blockers paired with radiotherapy has shown promise in preclinical murine GBM models. Human clinical trials have largely failed. One reason for this may be the discrepancy between radiation protocols utilized in preclinical models versus clinical practice. For translational relevance, definin…

New strategy enhances immunotherapy effectiveness against glioblastoma by utilizing gut microbes

Advanced treatments, known as immunotherapies that activate T cells—our body's immune cells—to eliminate cancer cells, have shown limited efficacy as standalone therapies for glioblastoma, the most lethal form of brain tumor.

Gut microbes and tryptophan enhance immunotherapy for difficult-to-treat brain tumors

Advanced treatments, known as immunotherapies that activate T cells—our body's immune cells—to eliminate cancer cells, have shown limited efficacy as standalone therapies for glioblastoma, the most lethal form of brain tumor. This is due to their minimal response to glioblastoma and high resistance to treatment.

Nektar Raises $115M in Oversubscribed Offering: Major Boost for Immunotherapy Drug Development

Biotech firm secures $115M through successful stock offering at $23.50/share, with strong investor demand. Funds target breakthrough immunotherapy advances. Learn more.

KAIST Boosts Immunotherapy Effectiveness Against Challenging Brain Tumors

In a groundbreaking advancement at the intersection of oncology, immunology, and microbiology, researchers at the Korea Advanced Institute of Science and Technology (KAIST) have unveiled a novel strategy that dramatically enhances the efficacy of immunotherapy against glioblastoma, the deadliest form of brain cancer. This revelation hinges on the intricate relationship between gut microbiota and the […]

Temferon Linked to Long-Term Survival in Some With Glioblastoma

Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized after initial progression.